Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.
Jon K. Snodgres joined Repligen in July 2014 as the Chief Financial Officer, where he oversees financial operations for the Company. Mr. Snodgres was previously with Maquet Cardiovascular (“Maquet”), a medical device company, where he served as Chief Financial Officer for five years. At Maquet, in addition to being responsible for the preparation and oversight of the company’s financial statements, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a B.S. in Business Administration, Finance from Northern Arizona University.
Chief Operating Officer
James R. Bylund was named Chief Operating Officer of the Company in January 2022 and serves as the Company’s principal operating officer. He joined Repligen in March of 2020 as Senior Vice President, Global Operations and IT, overseeing all operations and IT functions on a global basis. Between March 2019 and March 2020, Mr. Bylund also worked in real estate at Inspire Development in Austin, Texas. Prior to joining Repligen, Mr. Bylund spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division. Prior to joining Thermo Fisher, Mr. Bylund also worked for Fiserv (9 years) and Eli Lilly and Company (7 years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and an M.B.A. from Indiana University.
Senior Vice President, Filtration and Chromatography
Christine Gebski joined Repligen in May 2015 and currently serves as the Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolio. Ms. Gebski also manages the Customer Service and Field Applications functions within the Company, ensuring strong customer experience. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific. At Thermo Fisher she managed the Global Process Chromatography Applications and R&D functions for ten years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry having held positions of increasing responsibility at Genzyme, TKT/Shire and EMD Pharmaceuticals. She has significant experience in downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.
Ralf Kuriyel joined Repligen in October 2016 as the Senior Vice President, Research and Development where he oversees the Company’s R&D efforts. Mr. Kuriyel was previously Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.
Senior Vice President, Systems and Automation
Gautam Choudharyは2018年11月にバイオプロセスシステムおよびオートメーション部門の副社長兼ゼネラルマネージャーとしてRepligenに入社しました。TFFシステムのインフラ構築と戦略開発、連続生産のワークフローの推進を担当しています。Repligenに入社する前は、Lonza社で戦略的・運営的プロジェクトをサポートし、バイオサイエンスソリューションの細胞・遺伝子治療の市場投入戦略の開発に携わっていました。それ以前は、Life Technologies/Thermo Fisher社に12年間在籍し、バイオプロダクション向け細胞培養（Gibco）ビジネスをけん引してきました。さらにそれ以前は、アジアとヨーロッパに展開するMillipore社で、ろ過、クロマトグラフィー、システムビジネスをサポートする技術的および商業的な職務をいくつか経験しています。Choudhary氏はイギリスのリーズ大学で機械工学の学士号とマーケティングのMBAを取得しています。
2015年にRepligenに入社する前、Steve CurranはLife Technologies/Thermo Fisher Scientificで グローバルネットワークリーダーを務めていました。過去10年間で、Curranは世界中、複数のサイトにおけるグローバル遺伝子分析およびクロマトグラフィーの消耗品オペレーションを管理し、リーン手法を利用した高効率オペレーションを構築し、品質システムをアップグレードしました。彼はまた、厳しい規制要件を満たす2つの複数製品プラントの設計、建設、委託を主導しました。この職務に就く前は、バイオテクノロジー業界で15年間、開発エンジニアとしてさまざまなリーダーシップを発揮し、製品輸送、プロセスのスケールアップ、検証などの役割を担っていました。彼は、マサチューセッツ州ウースターのウースター工科大学にて、化学工学の学士号を取得しています。
Vice President and General Manager, Downstream Bioprocessing and Gene Therapy
Vikas Guptaは、2016年3月に事業開発・戦略担当の副社長として Repligenに入社しました。Repligenへの入社前は、GE Life Sciencesにて2012年から2015年まで、エンタープライズソリューション&サービスビジネスとシングルユースおよびフィルタリングポートフォリオを管理する商業的リーダーシップの役割を担っていました。GEへの入社前は、Millipreで2004年から2011年まで、ビジネス開発、製品管理の役割を担い、Mobiusのシングルユースバイオプロセシングビジネスの初期の成長に貢献しました。彼は、抽出物と浸出物の影響を評価する際のリスクベースのアプローチ、および使い捨て用品廃棄での持続可能性の取り組みにおける、初期の旗振り役の1人です。化学工学の学士号とMBAをインドで取得し、マサチューセッツ州ウォルサムのベントレー大学で金融の修士号を取得しています。
Senior Vice President, Analytics
Before joining Repligen in 2019, Craig Harrison served as the President and Founder of C Technologies, Inc. for over 35 years. Craig and his team worked closely with a wide range of industries to deliver fiber optic assemblies, instrumentation, and systems for spectroscopy applications that were designed and manufactured in-house. In 2008, he launched the SoloVPE® System that uses Slope Spectroscopy® that has become the standard for concentration measurement in the biotech industry. Craig leverages his background in business development and fiber optics in his current role at Repligen, where he focuses on Analytics. He holds a Bachelor’s degree in Economics from the University of Rochester.
Senior Vice President, Strategy and Business Development
Kola Otitoju joined Repligen in 2020 as Senior Vice President of Strategy and Business Development. He is responsible for leading the development and execution of the Repligen growth strategy including partnerships, licensing, investments and mergers and acquisitions. Mr. Otitoju brings a wealth of experience in strategic planning and execution having led multiple transactions in excess of $100BN through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities (8 years), large publicly traded corporations including Baxter and GE Healthcare (6 years), and private equity-backed companies like Candela Medical with Apax Partners (3 years). He also brings a strong technical background having been an Electrical Engineer earlier in his career. Mr. Otitoju has Masters Degrees in Business Administration from Harvard Business School and Electrical Engineering from Cornell University, in addition to a Bachelor's Degree in Information Systems Engineering from Imperial College London.
Vice President, Operations - Europe
Gustav Silfversparreは、 2013 and is managing Repligen manufacturing sites in Europe. Before coming to Repligen, Mr. Silfversparre was Operations Director at Novozymes Biopharma AB, which was acquired by Repligen in December 2011. Between 2008-2010, Mr. Silfversparre was Head of Biopharma Coordination, a global project and production coordination function for the biopharma area within Novozymes.From 2002 to 2008, Mr. Silfversparre was Head of the Development Department at Novozymes Biopharma AB. Mr. Silfversparre received a Tech. Lic. Biotechnology at Royal Institute of Technology and M.Sc. Chemical Engineering at the Faculty of Engineering, Lund University.
Vice President, Global Sales
Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: Vaccitech plc and Medicenna Therapeutics Corp, one private company, PaxMedica, Inc., and on one not-for-profit company, Medicines 360.
Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.
Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 30 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. (“Biogen”) for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy also serves on the board of directors of three publicly traded companies: Fluidigm Corporation, Twist Bioscience and 908 Devices Inc., and three privately held companies; Biocare Medical LLC, NanoCellect Biomedical, and Slingshot Biosciences. He also serves as an advisor to Warburg Pincus, a private equity firm. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.
Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.
Konstantin Konstantinov, Ph.D., has served as a director of Repligen since May 2022. He is also a member of our Scientific Advisory Board since March 2016. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.
Carrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 25 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics (“Quest”), which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab
services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In her role at Quest, Ms. Eglinton Manner is responsible for value creation across the company’s $10 billion clinical portfolio, driving innovation in R&D, along with partnerships and acquisitions. She has helped accelerate growth in Quest’s $2 billion Advanced Diagnostics portfolio, which includes its specialty molecular and genetic offerings, along with Quest’s global and pharmaceutical services businesses. She also serves as Executive Sponsor for Quest’s African-American Business Leaders Network. In addition to the Repligen Board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and transforming health in underserved communities in Southeast Asia. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.
Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture,
purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Company’s Board include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.
Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc. (“Hologic”), a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies: medical technology company, Neuronetics, Inc., and life science company G1 Therapeutics, Inc., and one privately held company: medical device company Impulse Dynamics Limited. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.
Richard D. Braatzは、マサチューセッツ工科大学（MIT）のEdwin R. Gilliland教授で、高度な製造システムのプロセスデータ解析、設計、制御の研究を行っています。カリフォルニア工科大学で修士号と博士号を取得し、イリノイ大学アーバナ・シャンペーン校のミレニアムチェアと教授、ハーバード大学の客員研究員を経て、マサチューセッツ工科大学（MIT）に移りました。Merck社、Novartis社、Pfizer社、Amgen社、Biogen社、Bristol-Myers Squibb社など、30社以上の企業とコンサルティングやコラボレーションを行ってきました。全米工学アカデミー会員です。
Charles L. Cooneyは、Robert T. Haslam（1911）化学・生化学工学教授、マサチューセッツ工科大学化学工学科名誉教授、マサチューセッツ工科大学デシュパンデ技術革新センター名誉所長です。ペンシルバニア大学で化学工学の理学士号を取得し、MITで生化学工学のSM（科学マスター）と博士号を取得。MITの教員としてキャリアを積んできました。プロセス設計、アップストリームおよびダウンストリームバイオプロセス開発、医薬品・バイオ製品の製造を得意としています。Cooney教授は、さまざまなバイオテクノロジー企業や製薬会社のコンサルタントや役員を務め、Repligenの科学諮問委員会の会長を務めています。
Cramer博士はレンセラー工科大学のWilliam Weightman Walker Processorであり、複雑な生物学的産物の分離や、そのバイオマニュファクチャリングを可能にするためのクロマトグラフィー材料、プロセス、予測ツールの開発に貢献したことで知られています。また、このような分離システムにおいてユニークな選択性を生み出す相互作用の分子理解にも多大な貢献をしてきました。現在、彼の研究室では、タンパク質の結合親和性の予測とクロマトグラフィーシステムのマルチスケールモデリング、効率的な抗体およびバイスペシフィック抗体分離システムの開発、マルチモーダルクロマトグラフィーの基礎研究、親和性ペプチド設計のためのマルチレベル自動ペプチド合成/スクリーニングシステム、スマートバイオポリマー親和性沈殿システム、タンパク質と表面、リガンドおよびタンパク質との相互作用の生物物理学、プロセスHCPの効果的な除去のためのプラットフォーム戦略、統合された半連続バイオマニュファクチャリングプロセスなど、タンパク質と表面の相互作用に関連するいくつかの分野の研究を行っています。『Separation Science and Technology』誌の編集者を20年間務め、Alan S. Michaels Award for the Recovery of Biological Products（ACS Division of Biochemical Technology）、ACS National Award in Separation Science and Technologyを受賞しています。また、レンセラー工科大学の優秀教員賞、工学部優秀教授賞、研究優秀賞も受賞しています。Cramer博士は、米国科学振興協会、米国化学技術者協会、米国化学会、米国医学生物工学研究所のフェローに選出されています。
Alfred Goldberg is a Professor of Cell Biology at Harvard Medical School. His research has concerned the mechanisms and regulation of protein breakdown in cells. His laboratory first demonstrated the existence of the non-lysosomal pathway for protein breakdown (now termed the ubiquitin-proteasome pathway), the 26S proteasome, and the ATP-dependent proteases responsible for protein degradation in bacteria. He also initiated the development of the proteasome inhibitor, Bortezomib/Velcade, now used worldwide for the treatment of multiple myeloma. His research accomplishments have been recognized with many honors, including three honorary degrees, the Gordon Alpert Prize, the Ernst Beutler Prize, and the 2021 Passano Award for Medical Research. He has been elected to the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts & Sciences, and he is among the 0.01% most cited authors in the life sciences. Dr. Goldberg has served frequently as a consultant to biotech companies and for 7 years served on the Board of Directors of Repligen.
Konstantin Konstantinov, Ph.D., has been a member of our Scientific Advisory Board since March 2016. He also serves as a director of Repligen since May 2022. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.
J. Christopher Loveは化学工学におけるRaymond A.（1921）and Helen E. St. Laurent Professorであり、MITのコッホ研究所の統合的癌研究のメンバーでもあります。また、Eli and Edythe L. Broad Institute、およびRagon Institute of MGH, MIT and Harvardのアソシエイトメンバーでもあります。Love教授は、2004年にハーバード大学で物理化学の博士号を取得しました。2004年から2005年までハーバード大学医学部、2005年から2007年まで免疫疾患研究所で免疫学の研究を広げました。彼の研究の中心は、慢性的なヒト疾患の臨床サンプルから細胞をモニターするためのシンプルなマイクロシステムの使用と、生物学的製剤やワクチンを効率的かつ安価に製造するための新しいアプローチの開発です。Love教授は、2009年にはDana Scholar for Human ImmunologyとKeck Distinguished Young Scholar in Medical Researchに選ばれ、2010年には『Popular Science』誌のBrilliant 10の1人に選ばれ、さらにCamille Dreyfus Teacher-Solarにも選ばれました。MITでは、バイオ医薬品やワクチンの新しい製造ホストを推進する、ユニークなMITと業界のパートナーシップであるオルタナティブホストコンソーシアムのディレクターを務めています。以前は、Biogen社のDistinguished Engineer in Residence（2015～2016年）を務めていました。また、MITでの彼の研究室の技術を基にした3つの新興企業（Honeycomb社、OneCyte社、Sunflower社）を含む、複数のバイオテクノロジーおよびバイオ医薬品企業のコンサルティングも行っています。